Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor.

Thorax · 2018 · PMC6204955 · PMID 29748252

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Several other microorganisms, including Staphylococcus aureus , showed a trend towards lower prevalence among ivacaftor-treated than among comparator patients in both registries ( table 2 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.